Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria

Lancet. 2024 Jan 13;403(10422):118-119. doi: 10.1016/S0140-6736(23)02188-8. Epub 2023 Nov 23.

Authors

Sarah Moussa¹, Elena Netchiporouk²

Affiliations

¹ Faculty of Medicine, McGill University, Montréal, QC, Canada.
² Division of Dermatology, Department of Medicine, McGill University, Montréal, QC, Canada; McGill University Health Centre, Montréal, QC H3G 1A4, Canada. Electronic address: elena.netchiporouk@mail.mcgill.ca.

PMID: 38008108
DOI: 10.1016/S0140-6736(23)02188-8

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Chronic Disease
Chronic Urticaria* / drug therapy
Humans
Omalizumab* / therapeutic use
Treatment Outcome

Substances

Omalizumab
ligelizumab
Antibodies, Monoclonal, Humanized